More than 15 years old, with $4.15M in SDE and roughly 29,000 active subscribers, this patented pediatric supplement brand has unusual scale and longevity for the category. It sells through Amazon, its own website, and approximately 45,000 pharmacy locations, with clinical support from a randomized controlled trial published in a peer-reviewed medical journal.
The numbers: Listed at $23M plus inventory on $14.17M in annual revenue and $4.15M in SDE. That works out to 1.6x revenue and 5.5x SDE, with a 29.3% margin. The seller reports that approximately 28% of revenue is recurring, or nearly $4M annually at the current run rate.
How it works: Amazon generates 65%–70% of revenue, although the seller says that concentration is declining as the higher-margin DTC channel grows. A small, tenured team handles Amazon, the website, operations, and brand management, while the longtime pediatrician Chief Medical Officer is available to remain after the sale.
The seller situation: The founder is retiring and is offering transition support, including introductions to physician and wholesaler relationships. That handoff matters because the patent, clinical credibility, and professional distribution relationships appear to account for a meaningful part of the brand’s defensibility.
Worth asking: How much patent protection remains, and how much revenue depends on physician, wholesaler, or pharmacy relationships that are still tied directly to the founder or Chief Medical Officer?
